Advertisement

memo - Magazine of European Medical Oncology

, Volume 11, Issue 4, pp 348–350 | Cite as

Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a rare case and review of literature

  • Amrita Chakrabarti
  • Nitin Sood
case report
  • 13 Downloads

Summary

Ruxolitinib is a Janus kinase (JAK) 2 inhibitor that is an effective therapeutic agent for primary myelofibrosis (PMF), which helps significantly to reduce constitutional symptoms and spleen size. However, this drug has significant immunomodulatory effects that may lead to various opportunistic infections. Reactivation of tuberculosis and certain viral infections have been well documented. Although a few reports of patients with pulmonary cryptosporidiosis on ruxolitinib exist, an extensive literature review shows only one previously reported case of cryptococcal meningoencephalitis in an immunocompetent patient on ruxolitinib, with a history of avian exposure. Here we report another extremely rare incidence of cryptococcal meningitis in a fully immunocompetent male patient on ruxolitinib, with no history of contact with birds. Although this is an approved and effective therapy for PMF, careful evaluation, screening, and prophylaxis in susceptible individuals should be considered before starting therapy.

Keywords

Ruxolitinib Primary myelofibrosis Cryptococcal meningitis Opportunistic infections Immunocompetent 

Notes

Conflict of interest

A. Chakrabarti and N. Sood declare that they have no competing interests.

References

  1. 1.
    Dioverti MV, Saleh AOM, Tande AJ. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. Infect Dis. 2017;50(5):381–7.  https://doi.org/10.1080/23744235.2017.1390248.CrossRefGoogle Scholar
  2. 2.
    McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep. 2015;10:370–9.CrossRefGoogle Scholar
  3. 3.
    Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.CrossRefGoogle Scholar
  4. 4.
    Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.CrossRefGoogle Scholar
  5. 5.
    Hirano A, Yamasaki M, Saito N, et al. Pulmonary cryptosporidiosis in a Ruxolitinib treated patient with primary myelofibrosis. Respir Med Case Rep. 2017;22:87–90.Google Scholar
  6. 6.
    Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of Ruxolitinib. Ann Hematol. 2016;95(2):361–2.CrossRefGoogle Scholar
  7. 7.
    Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with Ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143(5):1478–9.CrossRefGoogle Scholar
  8. 8.
    Seminario-Vidal L, Cantrell W, Elewski BE. Pulmonary cryptococcosis in the setting of Tofacitinib therapy for psoriasis. J Drugs Dermatol. 2015;14(8):901–2.Google Scholar
  9. 9.
    Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor Ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192–202.CrossRefGoogle Scholar
  10. 10.
    Parampalli Yajnanarayana S, Stubig T, Cornez I, et al. JAK1/ 2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169:824–33.CrossRefGoogle Scholar
  11. 11.
    Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187–99.CrossRefGoogle Scholar
  12. 12.
    Islam R, Yellu MR, Rafiullah, et al. Low-dose Ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis. Bmj Case Rep. 2013;2013(1)  https://doi.org/10.1136/bcr-2013-010068.CrossRefGoogle Scholar
  13. 13.
    Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843–4.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical Hematology & Bone Marrow TransplantMedanta-The MedicityGurgaonIndia

Personalised recommendations